-
Mashup Score: 1Feedkast - 2 year(s) ago
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myeloma – Myeloma Patients Europe The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies,…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Feedkast - 2 year(s) ago
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side EffectsMultiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time….
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: The role of Anti-B-Cell maturation antigen for managing MM in the #MultipleMyeloma feed: https://t.co/pGH0pm2eB3. #mmsm #MY…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma – Scientific ReportsMultiple myeloma (MM) is an incurable cancer of terminally differentiated plasma cells that proliferate in the bone marrow. miRNAs are promising biomarkers for risk stratification in MM and several miRNAs are shown to have a function in disease pathogenesis. However, to…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Identifying interactions between miRNA and mRNA in MM in the #MYELOMA feed: https://t.co/6aZstMd3U6. #MultipleMyeloma #mmsm…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma communityGSK plc announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit organisation helping patients learn more about their health and become their own best advocates. Their proposal,…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Results from the Phase III Determination Trial on MM and BC at ASCO 2022 in the #MYELOMA feed: https://t.co/fTDfdtmvX3. #AS…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
MagnetisMM-3: elranatamab in relapsed/refractory multiple myelomaAlexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Dr. Srour discusses CB-NK cells in High-Risk MM in the #MultipleMyeloma feed: https://t.co/W7GVbWy43O. #hematology #oncolog…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
Impact of Chronic Inflammation in Psoriasis on Bone MetabolismPsoriasis is a chronic inflammatory disease of the skin and joints associated with several comorbidities such as arthritis, diabetes mellitus and metabolic syndrome, including obesity, hypertension and dyslipidaemia, Crohn’s disease, uveitis and psychiatric and psychological diseases. Psoriasis has been described as an independent……
Source: www.feedkast.comCategories: Dermatology, Latest HeadlinesTweet-
RT @_Feedkast: Evaluating the correlation between Psoriasis and sleep disturbances in the #dermatology feed: https://t.co/OK4NP4fooU. #pso…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
The PROMISE study: What have we learnt about MGUS prevalence and clinical implications?During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Utilizing mass spectrometry to detect MGUS in the #MultipleMyeloma feed: https://t.co/22Cbv3Hyx7. #MYELOMA #mmsm #hematolog…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
Nikolaos Dimitrakakis on Artificial Bone Marrow and TeamworkNiko places a great importance on teamwork, which he learned from playing sports while growing up in Greece. At the Wyss, Niko is a team captain of sorts – he seems to know everyone’s name, encourages collaborative conversation among colleagues, and after eight years he certainly has demonstrated passion and spirit for the Wyss….
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Examining the efficacy of T-Charge CAR T-Cell in MM in the #myeloma feed: https://t.co/Kp8EGqgdLh. #MultipleMyeloma #mmsm #…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”Biomarkers of bone turnover in serum are suggestive of bone dynamics during treatment in multiple myeloma (MM). We evaluated the role of daratumumab on bone remodeling among patients with relapsed/refractory MM in the prospective, open-label, phase 2 study REBUILD. Daratumumab was administered…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Experts discuss treatment options in late-stage MM on @_Feedkast in the #MutipleMyeloma feed: https://t.co/WlmQx87edq. #mms…
-
-
Mashup Score: 1Feedkast - 2 year(s) ago
Recap: A Review of Multiple Myeloma Trials That Impact the Standard of CareA panel of experts provides a discussion on treatments for newly diagnosed transplant-eligible and transplant-ineligible relapsed multiple myeloma, and how recent clinical trial data presented at ASH 2021 can be applied to clinical practice.A panel of experts provides a discussion on treatments for newly diagnosed…
Source: www.feedkast.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @_Feedkast: Expert panel reviews MM trials and treatments in an article from @CancerNetwrk on @_Feedkast: https://t.co/984okED7rP. #mms…
-
RT @_Feedkast: Conditional approval granted to Teclistamab for MM treatment by EMA in the #MYELOMA feed: https://t.co/xSXb8RBcFF. #Multipl…